POS-569 EFFECT OF CILOSTAZOL ON ARTERIOVENOUS FISTULA IN HEMODIALYSIS PATIENTS

Abstract

The maturation and patency of permanent vascular access are critical in patientsrequiring hemodialysis. Although numerus trials have been attempted to achieve permanently patentvascular access, little have been noticeable. Cilostazol, a phosphodiesterase-3 inhibitor, has beenshown to be effective in peripheral arterial disease including vascular injury-induced intimalhyperplasia. We therefore aimed to determine the effect of cilostazol on the patency and maturation ofpermanent vascular access. This single-center, retrospective study included 194 patients who underwent arteriovenousfistula surgery to compare vascular complications between the cilostazol (n = 107) and control (n =87) groups. The rate of vascular complications was lower in the cilostazol group than in the controlgroup (36.4% vs. 51.7%; p = 0.033), including maturation failure (2.8% vs. 11.5%; p = 0.016). Therate of reoperation due to vascular injury after hemodialysis initiation following fistula maturationwas also significantly lower in the cilostazol group than in the control group (7.5% vs. 28.7%; p<0.001). However, there were no significant differences in the requirement for percutaneoustransluminal angioplasty (PTA), rate of PTA, and the interval from arteriovenous fistula surgery toPTA between the cilostazol and control groups. Cilostazol might be beneficial for the maturation of permanent vascular access inpatients requiring hemodialysis.